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Abstract
Metabolic cardiomyopathy and other heart disorders are associated with
proteostasis derailment and subsequent autophagy. Proteostasis is a process of
protein homeostasis, and autophagy is a mechanism of self-degradation for surviv-
ing cells facing stressful conditions. Metabolic challenges have been linked to excess
reactive oxygen species. Cardiomyocyte proteotoxicity, an important underlying
pathologic mechanism in cardiac disease, is characterized by chronic accumulation
of misfolded or unfolded proteins that can lead to proteotoxic formation or aggre-
gation of soluble peptides. Autophagic processes are mediated by the ubiquitin-
proteasome and autophagy-lysosome systems, fundamental for cardiac adaptation
to physiological and pathological stress. Cellular proteostasis alterations in cardio-
myopathy are represented by myocardial remodeling and interstitial fibrosis with
reduced diastolic function and arrhythmias. Autophagy regulation may be a poten-
tial therapeutic strategy for metabolic cardiomyopathy necessary for the treatment
of fibrosis and cardiac tissue remodeling alterations. Furthermore, autophagy has
been shown to be active in the perimeter of cardiovascular fibrotic tissue as mech-
anism of fibrosis recovery and scarring secondary to cell apoptosis. In the present
work, we review the current knowledge on the role of autophagy and proteostasis in
the pathogenesis of heart failure to resolve the ever-expanding epidemic of meta-
bolic cardiomyopathy and heart failure associated with substantial morbidity and
mortality.
Keywords: autophagy, proteostasis, cardiac hypertrophy, metabolic
cardiomyopathy, myocardial interstitial fibrosis, heart failure
1. Introduction
Metabolic cardiomyopathies can be caused by disturbances in metabolism and
may develop in the context of a broad spectrum of pathological conditions. These
disorders include a number of inherited metabolic diseases in early childhood
affecting the heart and other organs. Cardiomyopathies are associated with systemic
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metabolic diseases acquired during adulthood, such as metabolic syndrome,
dyslipidemia, obesity, hypertension, diabetes mellitus and cardiomyopathy by
alcoholism [1], which are also considered important causes of cardiovascular dis-
eases. Furthermore, abnormal mitochondrial function related to mitochondrial
ATP-producing capacity and high cardiac energy demand is linked to several of
these cardiovascular diseases. The heart is a high-energy-demanding organ and
mitochondria are important organelles that provide its source of cellular energy by
oxidative phosphorylation; however, enzyme deficiency related to mitochondrial
beta-oxidation leads to cardiac disorders. Another key point is that autophagic
activity has been found to decrease with age resulting in intracellular protein
aggregate accumulation, unfolded protein response activation and subsequent
cardiomyocyte apoptosis, likely contributing to the accumulation of damaged mac-
romolecules and organelles during aging. Equally important, several forms of heart
failure are progressive disorders associated with substantial morbidity and mortal-
ity, and of these, cardiovascular pathologies are the leading cause of death in the
elderly. Autophagy, a lysosome-mediated degradation pathway, plays a critical role
in proteostasis by removing potentially toxic cytosolic protein aggregates and dam-
aged organelles within cells [2]. Cardiomyocyte proteostasis is the gradual derail-
ment of cellular protein homeostasis important to protein quality control [3]. The
dysfunction in proteostasis leading to the accumulation of protein aggregates is the
hallmark of cardiovascular disease and many chronic and age-related diseases [4].
The metabolic syndrome has become one of the most important topics in recent
decades because of the marked increase in cardiovascular risk associated with the
clustering of risk factors [5]. Obesity is a major independent risk factor for cardio-
vascular disease, including cardiac hypertrophy and heart failure. Leptin, an
adipocyte-derived hormone, acts through its receptors (LepRs) on hypothalamic
neurons that regulate body weight and energy homeostasis. LepRs are also
expressed on cardiovascular cells, and leptin has also been shown to promote
cardiomyocyte hypertrophy, endothelial proliferation, migration and angiogenesis,
and fibrosis.
The effects of the mechanistic target of rapamycin (mTOR) are mediated
through its activity as a central inhibitor of autophagy, a highly conserved cell
survival mechanism. Cardiac hypertrophy is associated with increased energy
demands, and cellular stressors like ischemia or nutrient deprivation, which result
in the rapid regulation of myocardial autophagy. In this context, endothelial cells
are particularly sensitive to metabolic stress, and defective or maladaptive endo-
thelial autophagy may contribute to the rarefaction of the cardiac microvasculature
during hypertrophy, a critical event in the transition toward heart failure [6]. In the
present work, we review the current understanding of the role of autophagy and
proteostasis in the pathogenesis of heart disease, considering the essential involve-
ment of both degradation processes to find a novel therapeutic target to resolve the
ever-expanding epidemic of metabolic cardiomyopathy and heart failure associated
with significant morbidity and mortality.
2. Proteostasis
A complex proteostasis network functions to ensure the maintenance of
proteostasis, consisting of molecular chaperones and proteolytic machineries and
their regulators in healthy cells. Each type of these molecules with a precise amino
acid sequence has important physical properties to determine specific protein
structure and a three-dimensional conformation to proteins, which is important in
order to regulate cellular performance and balance. Protein structures are made by
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the formation of peptide bonds that build the polypeptide long chains of alpha-
amino acids, a common property of all proteins. Disturbed proteostasis in
postmitotic cell types, such as cardiomyocytes and neurons, produces an accumu-
lation of misfolded and aggregated proteins resulting in disease. These factors
coordinate protein synthesis with polypeptide folding for the conservation of pro-
tein conformation and protein degradation. In particular, maintaining proteome
balance is a challenging task against external and endogenous stresses that accumu-
late during chronic cardiovascular disease and aging, which lead to the decline of
the proteostasis network capacity and proteome integrity [4].
2.1 Balance and integrity of the proteome
The protein flux of the cell must remain in balance to ensure proper cell and
tissue function. The protein homeostasis, also known as proteostasis, leads to the
accumulation of protein aggregates and it is the cause of several diseases. In view of
this, protein aggregation is a common characteristic of many chronic diseases.
Proteome balance is a task in defiance of external and endogenous stresses that
accumulate in a lifetime, such as chronic cardiovascular diseases and aging. More-
over, regulated proteolysis mediated by proteases of damaged proteins is funda-
mental for protein quality control of eukaryotic cells that require the ubiquitin-
proteasome system (UPS). The UPS activity can be executed by ubiquitin-protein
ligases or chaperones and the first crucial step is recognition of a specific degrada-
tion signal (degron). Degrons are portions of a protein that when exposed create a
signal that is recognized by target proteins to the UPS pathway [7].
From this perspective, after several steps of substrate polyubiquitylation
followed by substrate unfolding and degradation, proteins with specific degrons are
recognized by the proteasome and targeted for degradation.
The cellular proteome is exceedingly complex and large-scale proteomic studies
have identified thousands of modification sites (common modifications include
phosphorylation, ubiquitylation, methylation and acetylation) in roughly 50% of
proteins in humans, the combinatorial nature of which is mostly unknown [8].
Individual proteins often exist in several modified forms and they also engage in
numerous dynamically regulated protein complexes during their life cycle. It is
estimated that about 100,000 distinct protein isoforms can be generated through
alternative splicing from all the pool of protein-coding genes. Nonetheless, the
mechanisms that underlie the dynamics, interactions, stoichiometry and turnover
of most individual protein species are poorly understood at the global level [8].
2.2 Proteostasis and its network
In the cell, the proteome is a wide surveillance and regulatory network of the
biogenesis process and protein degradation, which intervenes when these processes
develop in a suboptimal way [8]. Proteome imbalance often results in complex and
chronic diseases; therefore, it is a continuous process in order to meet the dynamic
of proteomic needs of the cell [8]. In healthy cells, a complex proteostasis network
(PN), comprised of molecular chaperones and proteolytic machineries and their
regulators, operates to ensure the maintenance of proteostasis. These factors coor-
dinate protein synthesis with polypeptide folding, the conservation of protein con-
formation and protein degradation [4]. The PN is performed by mechanisms
controlling protein biosynthesis, cotranslational folding process, trafficking,
neofunctionalization and degradation of proteins in vivo, among others, to maintain
proteome balance and conform to the PN [9].
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The proteome must have the ability to generate adequate synthesis, folding and
protein expression and at the same time to detect abnormalities during this process
by identifying the characteristics that force protective degradation when a compo-
nent lacks quality. Human cells have more than 103 proteins per cell, and 5% of
these are involved only in protein synthesis and turnover, and 60–80% of the
etiologies of some diseases are associated with misfolding proteins. Therefore, it is
clear that the constantly dynamic and complex eukaryote proteome requires a
tightly regulated process [10].
The description of cellular proteomes requires an understanding not only of how
proteins and their multimeric assemblies are built and their mechanisms established
but also of the rules that determine how proteins are selected for degradation when
they are unable to assemble properly with components of cognate networks. The
network is constantly regulating the proteome, but it responds to conditions of
proteotoxic stress by addressing the triage decision of fold, hold or degrade [11].
Consequently, the PN is constantly regulating the proteome and influences several
cellular functions by affecting their physiology and readapting through transcrip-
tional and translational changes within the biology of the cell [10, 11].
Numerous biological pathways affecting protein synthesis, folding, misfolding,
trafficking, disaggregation and degradation may adapt the PN by using proteostasis
regulators that can partially correct protein impairment, resulting in human dis-
eases by cell stress and aging. The main PN components include several modules
like protein synthesis machinery and the major mammalian protein degradation:
UPS that is central to the unfolding protein response (UPR), which is activated
when unfolded or misassembled proteins accumulate in the endoplasmic reticulum
(ER), and the armada of intra- and extracellular chaperones including proteases,
which detoxify cells from nonrepairable proteins [10, 11].
The structure of a determined protein is crucial for its function; hence, molecu-
lar chaperones are important components of the PN. Chaperones and other proteins
like oxidoreductases and glycosylating enzymes bind nascent proteins and assist in
proper folding into the correct structure and cellular location throughout their life
cycle [12].
Diverse agents modify the structure of proteins like aging, oxidative, and ther-
mal stress or misfolding-prone mutations. In this context, misfolded, damaged,
unnecessary or aggregated proteins should be degraded, or their interactions could
cause cell instability. There are two major intracellular proteolysis pathways: the
autophagy-lysosomal pathway and UPS [13]. The difference between these two
processes is the nature of the targeted protein degradation: in the case of autophagy,
it mainly acts in the cytoplasm, and for UPS, considered the main route of protein
degradation in mammalian cells, it acts on both cytoplasm and nucleus [14].
A deficient PN allows the disruption of cellular membranes by damaged proteins
or toxic aggregates, which interfere with cell function, and as a result, many meta-
bolic, oncological, cardiovascular and neurodegenerative disorders could appear in
the individual [15].
The UPS is a complex machine formed by numerous subunits that degrade
ubiquitin-attached proteins. This proteolysis pathway is critical for the quality
control of proteins by eliminating damaged proteins and also maintaining the con-
centration of many regulatory proteins of apoptosis, inflammation, signal trans-
duction and cell cycle [12]. The other proteolysis pathway, autophagy that is in
charge of degraded proteins, is not detected by the UPS, and it has an important role
in the immune response and starvation stage [16]. Autophagy eliminates several
dysfunctional cell components or catabolizes them when the cell is under starvation
and stress to maintain optimal levels of energy and nutrients [12]. ROS, DNA
damage or starvation activates this autoproteolysis pathway engulfing organelles in
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the autophagosome that are later fused with lysosomes, and by doing so, the amino
acids and fatty acids produced by the catabolism of the organelles are recycled in
the cytoplasm. However, three ways of delivering target proteins to the lysosome
have been identified, and based on this, autophagy is classified into three distinct
types: microautophagy, chaperone-mediated autophagy (CMA) and
macroautophagy [16].
In microautophagy, the cellular contents are invaginated directly by the lyso-
some. The major cytosolic chaperone systems are HSP70 and HSP90, which are
connected to the UPS pathway. The proteasome complex contains the proteolytic
active sites in the core particle (20S) and the regulatory activity of the holo-complex
in the regulatory particle (19S). The UPS pathway only recognizes polyubiqui-
tination proteins, a process that requires three enzymes: E1 ubiquitin activator, E2
conjugase and E3 ligase, which act sequentially. The polyubiquitylated proteins are
recognized by the core particle for their degradation by the regulatory particle (19S)
[17]. Meanwhile, CMA uses the molecular chaperone, known as heat shock cognate
71 kDa protein (Hsc70), for recognition of the KFERQ sequence motif in cytosolic
proteins that must be degraded, and drives them to the lysosome membrane [18].
The transmembrane receptor or docking protein is a lysosomal-associated mem-
brane protein-2A (LAMP-2A) that transports the unfolded cytosolic proteins into
the lysosome [18].
Macroautophagy involves the formation of the autophagosomes, defined as
special structures that invaginate cellular contents or target proteins and then
transport them to the lysosome. Besides eliminating pathogens, autophagy is also
required for antigen presentation by the major histocompatibility complex (MHC)
class II. The major autophagy pathway used by cells is the MHC class II [16].
2.3 Cardiomyopathy, cellular proteostasis alterations and myocardial
remodeling with interstitial fibrosis
Diabetic cardiomyopathy (DC) is a specific heart muscle disease that increases
the risk of heart failure and mortality in diabetic patients independent of vascular
pathology. Basal level autophagy plays a housekeeping role to maintain cellular
homeostasis. However, autophagy mechanisms are impaired in diabetic hearts. In
this sense, diminished autophagy limits cardiac injury in type 1 diabetes and
inhibited autophagy contributes to cardiac injury in type 2 diabetes. In this context,
protein homeostasis is a necessity for the correct function of the cell, in other words,
an interaction between protein synthesis, transport, post-translational modification
and degradation [17]. However, an accumulation of defective proteins results in
proteotoxicity or disturbed proteostasis. Progression of cardiovascular diseases due
to proteostasis alterations has been related with interstitial fibrosis and altered
myocardial remodeling. Recent evidence indicates that the progression of ventricu-
lar dysfunction may be associated with changes in the process of autophagy and
impaired proteostasis.
Autophagy in the mitochondria is a necessary process for maintaining a healthy
mitochondrial network, also known as mitophagy. Under pathological conditions,
mitochondrial dysfunction and enhanced ROS generation associated to cardiac
hypertrophy and impaired left ventricular function with increased aggregation of
abnormal proteins and enlarged or collapsed mitochondria can be found, such as
structural and functional remodeling with changes in composition of the extracel-
lular matrix, which are characterized by fibrotic tissue, impaired vascular and
coronary microvascular function or effects on subcellular cardiomyocyte composi-
tion (Figure 1). Thus, mitophagy has been shown to be essential for myocardial
protection [19]. In addition, calorie restriction is sufficient to accelerate cardiac
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autophagic flux and reduce mitochondrial oxidative damage in the heart, results
that suggest the important role of autophagy for maintaining optimal mitochondrial
structure and function [20].
Proteostasis and autophagy are related to various heart diseases; however, both
mechanisms can be beneficial or harmful depending on age and pathology. From
this standpoint, heart diseases linked to autophagy due to degradation of contractile
heart proteins are associated with cardiac aging, inherited cardiomyopathy, diabetic
cardiomyopathy (DC), atherosclerosis, heart failure (HF) and atrial fibrillation
(AF) [20]. The quality of cardiomyocytes depends on the efficient elimination of
damaged proteins by autophagy. The mechanism performed by chaperone proteins,
particularly heat shock proteins (HSP70/HSP40/HSP110) and chaperonins like the
T-complex protein 1 ring complex (TRiC), takes place to a greater extent in the
heart in response to oxidative stress [21]. HSPs are found in specific protein regions
to prevent aggregation; these HSPs regulate oxidative stress (OS) and metabolism
and maintain proper cell proliferation. The imbalance in the degradation of dam-
aged intracellular proteins induces aging of the heart muscle fibers as a result of OS,
the deterioration of the Ca+2 transits and the excessive generation of ROS. This
process affects remodeling, favoring hypertrophy and cardiac fibrosis [22].
In cardiomyopathies, the accumulation of incorrectly folded proteins or
acquired dysfunction of protein quality control has been implicated in impaired
proteostasis. The cellular function in the myocardium follows the regulation of
proteostasis and autophagy in order to control the quality of new synthesized pro-
teins and removal of unfolded/misfolded proteins. When UPS targets are too large
to be degraded by the proteasome, the autophagy system must control degradation
through the selection between UPS and autophagy. Among autophagy regulators,
the endosomal sorting complex required for transport protein complexes (ESCRT)
affects the lysosome-autophagosome fusion. Part of ESCRT is the charged
multivesicular body protein 2B (CHMP2B), which is required for autophagy. The
work of Zaglia et al., in 2014, identified a novel link between UPS and autophagy
and showed that the muscle-specific ubiquitin ligase atrogin-1 controls turnover of
the ESCRT-III family protein CHMP2B, which controls the autophagy signaling
pathways [23].
Transforming growth factor β1 (TGF-β1) is an important regulator of
fibrogenesis. Its expression is regulated by biochemical stimuli, as a humoral
response to infections, glucose and pH [24]. Binding of TGF-β1 to specific cellular
Figure 1.
Factors involved in autophagy and proteostasis in metabolic cardiomyopathy. Many proteins participate in the
activation and formation of the autophagosome. TGF-β1 induces the activation of signaling pathways such as
Smad, which in turn activates the formation of fibrogenic proteins such as type 1 collagen and fibronectin, and
these induce hypertrophy and cardiac fibrosis generating cardiac damage and activating autophagy in
cardiomyocytes. Modified of Kobayashi et al. [19].
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receptors, such as TGF-β type II and RII, activates phosphorylation for intracellular
signaling pathways, such as Smad2 and Smad3 [25], which induce the expression of
fibrogenic proteins like type I collagen and fibronectin [26]. These pathways trig-
ger an inappropriate deposition of collagen in cardiac fibers, causing impaired
heart function [27]. However, in other cell lineages, TGF-β1 is also capable of
inducing autophagy, so the regulatory mechanisms between the two events are
unknown [26].
Many target molecules are involved in fibrosis including the multiprotein com-
plex formed by phosphoinositide 3-kinase class III (PI3K) dependent on Beclin 1,
which regulates vesicular autophagy by activation of signaling pathways, such as
Akt, and, in turn, increases the expression of TGF-β for the development of fibrosis
[28]. HSP25 and alpha B-crystallin are expressed to a lesser extent in the heart;
however, they fulfill the function of chaperone proteins that favor stability between
actin and desmin, thus avoiding cardiotoxicity [29]. PINK1 (PTEN-induced puta-
tive kinase 1) is another protein involved in autophagy. It is located in the outer
membrane of defective mitochondria, and it favors autophagy through the recruit-
ment of the Parkin protein to depolarized mitochondria of cardiomyocytes [30].
These mechanisms can induce deregulation of autophagy by apoptosis in type II
cells in cardiac tissue, which leads to the development of myocardial infarction (MI)
[31]. Moreover, autophagy has been shown to be active in the perimeter of cardio-
vascular fibrotic tissue as a mechanism for fibrosis recovery and scarring secondary
to cell apoptosis [32]. Many molecules protect against type 1 diabetes–induced
cardiac dysfunction by activating autophagy. Lastly, the inhibition of autophagy has
a beneficial effect on type 2 diabetes–induced cardiomyopathy [33].
2.4 Mitophagy and redox dysregulation
Cardiomyopathies as a result of excessive ROS production and protein modifi-
cations in the mitochondria involve abnormal mitochondrial function resulting in
cardiac disorders due to the high energy demand of the heart through this organelle,
considered as a source of cellular energy production and mitochondrial ATP pro-
duction achieved by oxidative phosphorylation and beta-oxidation. As a result of
mitochondrial damage, the process of autophagy, known as mitophagy, is essential
for myocardial function and protection [19].
The physiological performance of endothelial nitric oxide synthase enzyme
(eNOS) is important for NO production, which is dependent on L-arginine through
its reaction with O2 and the constitutive eNOS dependent on Ca
2+/calmodulin, as
well as the cofactors (6R-)5,6,7,8-tetrahydrobiopterin (BH4), nicotinamide adenine
dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD) and flavin
mononucleotide (FMN). Nitric oxide (NO) produced by the endothelium from
eNOS, which is oxidized to L-citrulline and NO, works through the transference of
electrons from NADPH via FAD and FMN. Both eNOS constitutive activation
events are dependent, and in caveolae, they are Ca2+/calmodulin concentration
dependent [34].
Under pathological situations and in the presence of uncoupled eNOS, increased
OS is produced, instead of producing NO after eNOS activation due to the reaction
with reduced BH4 levels and upregulated NADPH. As a result of these cardiovascu-
lar (CV) risk factors, NO is not produced, but there is ROS production. These
abnormal reactions due to CV risk factors reduce bioactive NO [34].
The biological abnormalities produced by excessive ROS production such as
superoxide anion (dO2), hydrogen peroxide (H2O2) and hydroxyl radical (dOH)
species [35], including the rapid interaction of O2
 with NO, result in the loss of
NO bioavailability and increased production of peroxynitrite (ONOO) [34].
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The harmful overproduction of these ROS and protein mitochondrial modifications
as a result of impaired redox and pathological signaling in the CV system mediate
regulation of the most important ion channels, transporters and kinases related to
heart diseases.
These mechanisms lead to selective cardiac dysfunction and decreased energy
production due to reductions in mitochondrial respiration, increased OS and defec-
tive contractile Ca2+ regulatory proteins. These types of changes and alterations in
mitochondrial biogenesis, content and function related to an heterogeneous group
of cardiovascular disease risk factors like metabolic syndrome, have been
documented. Damaged mitochondria are degraded through mitophagy, the main
protective function of autophagy that is for myocardial protection and the target of
successful drug development emerging in the cardiovascular space. These strategies
may be applied upon several redox targets, such as the membrane caveolae region
where key cardiovascular redox proteins, such as eNOS, calmodulin and NADPH
oxidase, among other important cardiovascular-related receptors, are located. Thus,
calorie restriction is sufficient to accelerate cardiac autophagic flux to help improve
mitochondrial oxidative damage and to maintain a healthy mitochondrial network
[11, 18, 19].
3. Autophagy
Dr. Christian de Duve was the first to use the term “autophagy,” meaning “self-
eating” in Greek, at the Ciba Foundation Symposium on Lysosomes, which took
place in London on February 12–14, 1963 [36]. When there is a functional decline in
the cardiovascular system and aging, cardiomyocytes need a cellular control mech-
anism to minimize damage and prevent cardiac malfunction. In this context,
autophagy may degrade and recycle long-lived proteins, cytoplasmic components
and organelles [37]. The notion of autophagy as cell death is a phenomenon that has
been controversial and remains mechanistically undefined. It should be noted that
when autophagy promotes cell death, there is an association of autophagy with the
different cell death pathways [38].
The biogenesis of an autophagosome is orchestrated by the so-called autophagy-
related (ATG) proteins, which act in a hierarchical order to first generate the
phagophore and then expand it into an autophagosome. The mammalian homologs
of ATG1 are the uncoordinated-51-like kinases 1 and 2 (ULKA1 and ULK2) ULK
complex, the ATG9A cycling system and the autophagy-specific class III
phosphatidylinositol 3-kinase (PtdIns3K) complex, which are key in generating the
phagophore upon induction of autophagy [39]. Besides, knockdown of EP300 and
the inhibition of histone acetylases potentially induce autophagy indicating that
protein deacetylation may play a role in the autophagic cascade. EP300 acetylates
several autophagy-related proteins, including autophagy-related 5 (ATG5), ATG7,
ATG12 and microtubule-associated protein 1 light chain 3 β (LC3). Lastly, protein
deacetylation influenced by several proteins controls autophagy at diverse levels
from the modification of autophagy core proteins to transcriptional factors control-
ling autophagic genes [39].
3.1 Autophagy basics
Autophagy is also considered an evolutionarily conserved process critical for
cellular homeostasis [3]. Implication of either the pathogenesis or the response to a
wide variety of diseases by autophagy has been related to the pathogenesis of
various disease states and to the basic molecular pathways that regulate autophagy
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[40]. Basal levels of autophagy maintain cellular homeostasis, and under stress
conditions, high levels of autophagy are induced. However, the pro-death role of
autophagy is complicated due to the extensive cross-talk between different signal-
ing pathways [38]. Autophagy is a process by which cytoplasmic components are
sequestered in double membrane vesicles and degraded upon fusion with lysosomal
compartments. Depending on the stimulus, autophagy can degrade cytoplasmic
contents nonspecifically or it can target the degradation of specific cellular compo-
nents. Higher eukaryotes have adopted both of these mechanisms and account for
the expanding role of autophagy in various cellular processes, as well as they
contribute to the variation in cellular outcomes after induction of autophagy. As the
basic molecular pathways that regulate autophagy are elucidated, the relationship of
autophagy to the pathogenesis of various disease states becomes apparent [40].
Autophagy is a highly conserved eukaryotic pathway responsible for the lyso-
somal degradation (and subsequent recycling) that is rapidly growing and elucidat-
ing an intriguing mechanistic complexity as well as a tremendous range of cargo
substrates. Imbalances in proteostasis are connected to aging and multiple (age-
associated) disorders [41]. Several pathologies including cardiovascular disease and
stress-related disorders are associated with autophagy dysregulation. Moreover,
excessive or insufficient levels of autophagic flux have been characterized in
cardiomyocytes, cardiac fibroblasts, endothelial cells and vascular smooth muscle
cells within the cardiovascular system [42]. Damaged and potentially cytotoxic
mitochondria elicit an autophagic response termed mitophagy. Depending on the
initiating stimulus, the substrate selection could differ. Thus, mitophagy takes part
in physiological processes like the removal of paternal mitochondria during egg
fertilization, and it is also a key process for the removal of damaged mitochondria in
toxic conditions [43]. Furthermore, autophagy stimulation may result in reduced
accumulation of misfolded and aggregated proteins; however, the overactivation of
autophagy can trigger autophagy-mediated apoptosis.
3.2 Autophagy and heart diseases
The cardiovascular system has the ability to adapt to a wide range of environ-
mental stresses. The myocardium itself manifests robust plasticity for both physio-
logical and pathological stimuli. From this perspective, autophagy is an intracellular
process required to maintain cardiovascular homeostasis, and it is also an evolu-
tionarily ancient process of intracellular catabolism in response to a wide variety of
stresses. In the case of postmitotic cells, where cell replacement is not an option,
finely tuned quality control of cytoplasmic constituents and organelles is especially
critical [41]. Mitochondrial DNA has an important role at inducing and maintaining
inflammation in the heart that escapes from autophagy. These autophagic mecha-
nisms degrade damaged mitochondria through fusion of autophagosomes and
lysosomes. Lastly, the impairment of mitochondrial cristae affecting cardiac
morphology and function is induced by pressure overload [44].
3.3 Regulation of autophagy in the heart
Excessive caloric intake results in obesity, a major independent risk factor for
cardiovascular disease, including cardiac hypertrophy and heart failure. From this
standpoint, cardiac remodeling is modulated by overnutrition or starvation. The
adipokine leptin mediates energy balance between adipose tissue and the brain.
Leptin and its receptors (LepRs) are expressed in the heart. LepRs belong to the
class I cytokine receptor family signaling via JAK (Janus kinase)-2 and signal trans-
ducer and activator of transcription (STAT)-3. In addition, nutrient signaling
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mediators, such as mTOR (mammalian target of rapamycin), induce LepR-
mediated activation of Akt. Cellular hypertrophy, proliferation and survival play an
important role in cardiovascular function and pathology mediated by the Akt/
mTOR pathway [45]. To examine the importance of endothelial leptin signaling in
cardiac hypertrophy, transverse aortic constriction was used in mice with inducible
endothelium-specific deletion of leptin receptors (End.LepR-KO) or littermate
controls (End.LepR-WT). Histology and quantitative polymerase chain reaction
analysis confirmed reduced cardiomyocyte hypertrophy. STAT3 activation was
reduced, and Akt (protein kinase B) and mTOR phosphorylation after transverse
aortic constriction were blunted in End.LepR-KO mice hearts [46].
For normal cardiac physiology in response to pressure overload (PO), mTORC2
is also required to ensure cardiomyocyte survival. It has been observed that
dysregulation of autophagy in cardiomyocytes is implicated in various heart disease
conditions. In these cases, vigorous protein quality control (PQC) systems are
essential for maintaining the long-term well-being of nonproliferating mammalian
cells, such as neurons and cardiomyocytes (CMs) [47]. Similarly, PO activates
autophagy in at least an acute phase and the suppression of PO-induced autophagy
that alleviates pathological cardiac remodeling. Recent investigations revealed that
enhancing autophagy ameliorates desmin-related cardiomyopathies, which are
inherited cardiomyopathies that result in severe heart failure due to protein aggre-
gation and myofibrillar disarray in CMs [47].
3.4 New therapeutic objective of metabolic cardiomyopathy in autophagy
Perturbations in autophagy are involved in virtually all stages of cardiovascular
disease. Research in the last decade has revealed that autophagy in cardiomyocytes
plays a protective role, but not only during hemodynamic stress, but also in
homeostasis during aging, resulting in mitochondrial damage. These damaged
mitochondria are degraded through mitophagy and this process could be the main
protective function of autophagy in the heart. From this standpoint, the mTORC1
complex regulates numerous biological processes, including proliferation, protein
synthesis and autophagy inhibition. In addition, the mTORC1 pathway inhibits
phosphorylation of the ULK1 protein (Ser 757) [48] considered an important ele-
ment of autophagy activation.
The effects of mTOR are mediated through its activity as a central inhibitor of
autophagy, a highly conserved cellular survival mechanism by which nutrient-
deprived cells refresh the bioavailability of metabolic precursors [6]. In the cardio-
vascular system, the mTOR pathway regulates the physiological and pathological
processes in the heart. In this regard, mTORC2 is necessary to maintain normal
cardiac physiology and it ensures the survival of cardiomyocytes that have been
subjected to PO. However, partial genetic or pharmacological inhibition of
mTORC1 has been shown to reduce cardiac remodeling and heart failure in
response to PO and chronic myocardial infarction. Therefore, mTOR may be a
therapeutic strategy to confer cardioprotection [45].
Nonetheless, depending on the context, autophagic flux may be biased up or
down. A large body of preclinical evidence suggests that autophagy is a double-
edged sword in cardiovascular disease, acting in either beneficial or maladaptive
ways, depending on the context. Modulation of Beclin 1 significantly influences
both autophagy and apoptosis, thereby deeply affecting the survival and death of
cardiomyocytes in the heart. This is the reason why it is important to discuss the
signaling mechanism of autophagy modulation through Beclin 1, including the
therapeutic potential of Beclin 1 in heart diseases [49]. In light of this, the
autophagic machinery in cardiomyocytes and other cardiovascular cell types has
10
Cardiovascular Risk Factors in Pathology
been proposed as potential therapeutic targets. Autophagy mediators hold promise
as targets for cardiovascular disease therapy; however, recent evidence suggesting
that titration of autophagic flux holds potential as a new therapeutic goal for car-
diovascular diseases, and heart failure, needs to be analyzed further [40].
3.5 Treatment for autophagy
The use of pharmacological modulators can be beneficial for the treatment and
prevention of autophagy. It is known that many agents or procedures induce or
reduce autophagy activity; among these are spermidine, carvedilol, trehalose, res-
veratrol, metformin, caloric restriction, exercise training, intermittent fasting and
ischemia/reperfusion.
Fasting and calorie restriction are the most potent nongenetic autophagy stimu-
lators related to autophagy promotion. Regarding the upregulation of autophagy,
the evidence overwhelmingly suggests that autophagy has to be induced in a wide
variety of tissues and organs in response to food deprivation. From a mechanistic
point of view, age-related vascular remodeling is driven by a greater accumulation
of ROS. Thus, the induction of autophagy per se is sufficient to extend the shelf life
in various species ranging from yeast to mammals [50]. Therefore, in addition to
preserving the homeostasis of organisms in baseline physiological conditions,
autophagy also contributes to metabolic fitness and the adaptation to stressful
conditions, such as nutrient deprivation, hypoxia, OS or physical exercise.
Autophagy is a critical process for cell homeostasis and survival, and it is also
implicated in the reduction of OS and inflammation. Furthermore, autophagic
processes have been associated with a greater expression of eNOS and bioavailabil-
ity of the protein. Long-lived, damaged, dysfunctional and potentially harmful
cellular components break down for detoxification, energy production and cell
renewal, providing building components and stimulating anabolic processes for
effective cell recycling.
Vascular induction of NO production as a response to shear stress during exer-
cise with augmented blood flow and increased flux sanguin over endothelial cells
(EC) result in eNOS activation and NO production. Autophagic process has been
related to greater expression of eNOS and bioavailability of the protein. ATG3 is an
important autophagy pathway mediator; in contrast with a reduction of 85% by
knockdown of ATG3 protein expression using control siRNA upon exposure to
shear stress showed impairment of eNOS activation and as a result were incapable
of produce NO as a response to shear stress. Autophagy is a critical process for cell
homeostasis and survival is also implicated. Long-lived, damaged, dysfunctional
and potentially harmful cellular components break down for detoxification, energy
production and cell renewal, providing building components and stimulating ana-
bolic processes for effective cell recycling as a result of autophagy [51].
3.5.1 Exercise-mediated regulation of autophagy
Substantial evidence indicates that exercise training plays a beneficial role in the
prevention and treatment of CV diseases. The regulation of autophagy during
exercise is a bidirectional process. Autophagy is a physiologic process that is a
defense mechanism for cells in adverse environments and it is also involved in
several pathological processes [52]. Autophagy normal levels confer cell protection
versus environmental stimuli to balance and protect organisms [53]. In this context,
various diseases are the response to excessive or insufficient autophagy. Exercise
training, referring generally to the cardiac adaptation to exercise, which has to be in
an appropriate intensity as a chronic stimulation process, can reduce the risk of CV
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diseases and improve the prognosis of patients after CV events. This type of training
can also reduce the production of ROS, reduce the inflammatory response, regulate
collagen metabolism, moderate the imbalance of extracellular matrix synthesis and
degradation, and alleviate cardiac fibrosis [54].
3.5.2 Intermittent fasting
Calorie restriction and stimulation of autophagy have healthy effects on the
lifespan and cardioprotection in humans. Intermittent fasting induces adverse ven-
tricular remodeling and cardiomyocyte death in null mice with LAMP2 (lysosome-
associated membrane protein 2) associated with an impaired autophagic flow. The
study of Godar et al. [54] highlights that intermittent fasting conferred
cardioprotection in wild-type female mice, with an 50% reduction in infarct size
compared to controls matched without fasting, and this cardioprotection was lost in
heterozygous null mice for LAMP2. One of the characteristics of these heterozygous
null mice is the accumulation of damaged mitochondria with a deteriorated basal
autophagic flux even on a fed day fed after 6 weeks, which probably results in the
loss of cardioprotection observed with this regimen in wild-type mice. Intermittent
fasting modulates OS from the myocardium through the effects on the mitochon-
dria, where it is lost in the context of LAMP2 ablation due to the deterioration of
mitochondrial autophagy [55]. Recent studies have discovered a potential mecha-
nism for transcriptional replacement of autophagy-lysosome machinery with star-
vation. In addition, a central role was attributed to dephosphorylation and the
cytoplasm induced by rapid hunger to nuclear translocation of TFEB (EB transcrip-
tion factor) [55]. The endogenous TFEB-mediated stimulation of the autophagic
flow is essential for the cytoprotective effects of repetitive hunger in hypoxia-
reoxygenation injury. The research group suggests the hypothesis that the tran-
scriptional replenishment of the autophagy-lysosome machinery by fasting (and
hunger as described earlier) may be a critical determinant of beneficial autophagy,
which allows living organisms to survive in what has probably been one of the first
evolutionary stresses that accompanied the origin of life [56].
Therefore, starvation (total caloric restriction) is a potent stimulus for the
induction of myocardial macroautophagy (called “autophagy”) [57–59]. It is already
known that autophagy is essential for cardiac homeostasis in the period of perinatal
hunger at birth; this effect is observed before the establishment of breast milk
supply [60]. In experiments using mice with genetic ablation of autophagy proteins
ATG5 and ATG7, autophagosomes could not be formed and fatal myocardial ische-
mia developed [60, 61]. In this respect, autophagy is also essential for the mainte-
nance of cardiac structure and function during prolonged starvation in mice, since
the concomitant deterioration of autophagy with FOXo1 genetic ablation, Becn1
haplo-insufficiency [57] or pharmacological inhibition with bafilomycin A1 [62], an
inhibitor of acidification and lysosome function, produces a rapid development of
cardiomyopathy with starvation.
3.5.3 Ischemia/reperfusion
The different roles of autophagy in cardiomyocytes exposed to varying degrees
of ischemia/reperfusion injury (I/R) or severe anoxia (S/A) were explored, and it
was observed that the autophagic activity of cardiomyocytes increased with an
increment in ischemia that was dependent on the duration of anoxia, undergoing
ischemia, or severe ischemia [63].
During the process of cardiac ischemia, the restriction in the blood supply and
the reduction of ATP leads to an imbalance in the amount of blood and energy,
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causing cell heart dysfunction and myocardial damage, inflammation and excess of
ROS production leading to cardiomyocyte death. It should be noted that ATP levels
can be monitored by adenosine monophosphate-activated protein kinase (AMPK),
which functions as a nutrient deprivation sensor in response to a decreased ATP
level during cardiac ischemia [64].
In the initial phase of ischemia, a low level of ATP activates AMPK in
cardiomyocytes. Once activated, AMPK directly phosphorylates and activates ULK1
resulting in the induction of autophagy by modifying ULK1 directly or indirectly
[48]. The pathway by which AMPK activates autophagy is through AMPK/
mTORC1 signaling. AMPK inhibits mTORC1 through phosphorylation of TSC2 and
the raptor site, followed by indirect activation of ULK1 [48]. Recent studies
revealed new pathways through which AMPK activated autophagy. Also, AMPK
directly phosphorylates and activates activated ULK1, allowing the onset of
autophagy [65–67]. Also, in the early I/R process, ROS modify the function of Ca2+
channels and exchangers, which triggers a decrease in available ATP, and thus,
directly affect the autophagy process [68].
Beclin 1 is an important autophagic protein that has been shown to regulate both
the formation and processing of autophagosomes, especially in the reperfusion
phase. An in vitro study revealed that autophagic response to nutrient deprivation
mediated by Beclin 1 is modulated by the Bcl-2 protein in cardiac cells [69]. More-
over, it has been observed that ROS can also be strong inducers of Beclin 1 in
mediating autophagy during the reperfusion phase [70]. In addition to regulating
Beclin 1 expression, ROS could also oxidize and decrease ATG4 activity, contribut-
ing to LC3 lipidation at the start of autophagy [71].
Cellular stress by ischemia, hypoxia, depletion of intracellular Ca2+ stores,
induced OS and ROS, and the accumulation of unfolded/misfolded proteins induce
ER dysfunction known as ER stress, and then the unfolded protein response (UPR)
is generated to deal and play a critical role in cell death after myocardial I/R injury.
Several transcription factors are induced by ER stress and the UPR whose branch
includes ATF6, inositol-requiring enzyme 1 (IRE1) and PKR-like ER kinase (PERK)
activated by I/R injury, which is the mediated signal pathway of UPR. The activat-
ing transcription factor 6 alpha (ATF6) is an ER transmembrane protein and most
ATF6-induced proteins localize to the ER [72].
Catalase is an enzyme that has been shown to decrease damaging ROS in the
heart. ATF6 induces catalase known to decrease ROS and reduce I/R damage in the
heart. Catalase is a component of peroxisomes that has also been found in the
cytosol and cardiac mitochondria, and it neutralizes H2O2 and also serves to oxidize
ONOOd, NO and organic peroxides; however, it has not be found in the ER. In the
study by Jin et al. [72], they examined the effects of blocking ATF6-induced pro-
teins in the ER stress response on I/R injury in cardiac myocytes and mouse hearts.
The role of ATF6 as a link between ER stress and OS and its effect on I/R myocardial
injury show an important function for ATF6, which binds to specific elements in
the regulatory elements of the catalase gene inducing its transcription [72].
Myocardial I/R injury negatively regulates protein synthesis, leading to the acti-
vation of signaling pathways from the ER to the cytosol and nucleus, representing
UPR and ER-associated protein degradation (ERAD). Most of I/R damage is caused
by ROS generated outside the ER. The study by Zhang et al. revealed that all the
three branches of UPR pathway are involved. Moreover, they demonstrated
reduced myocardium damage in I/R surgery, while the activation of UPR had
opposite effects. The results of this study were shown after the inhibition using a
standardized animal model with Sprague-Dawley rats that were pretreated with
UPR stimulator dithiothreitol (DTT) and UPR inhibitor 4-phenylbutyrate (4PBA)
and then subjected to myocardial I/R surgery [73].
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Under the cardiac I/R condition, increased autophagic activity compensated for
impaired UPS function, thereby maintaining proteolysis at an appropriate level.
However, cooperation between UPS (short-lived proteins) and autophagy (long-
lived proteins) is considered a housekeeping mechanism for protein quality control
in I/R injury. Thus, this increased autophagic response helps to maintain an ade-
quate proteolysis level and proteostasis in order to compensate impaired UPS func-
tion under cardiac I/R condition, which ultimately results in degradation by the
proteasome as well as autophagy.
3.5.4 Spermidine
Spermidine (SPD) is a type of polyamine that has been shown to enhance heart
function to delay cellular and organismal aging and provide cardiovascular protec-
tion in humans. Initially, the cardioprotective effects of SPD were explored in
rodent models of physiological cardiac aging (mice) and congestive heart failure
induced by high salt concentration (rats) [74]. SPD in the diet of mice delays
cardiac aging by improving diastolic function.
Furthermore, the evidence demonstrated that a high intake of SPD in the diet
was correlated with a reduction in the incidence of cardiovascular diseases. In
humans, high levels of SPD (natural polyamine) in the diet, as assessed by food
questionnaires, correlated with reduced blood pressure and a lower incidence of
cardiovascular disease. Subsequently, SPD was identified as a potent inducer of
autophagy [74]. SPD by increasing autophagic and mitophageal activity improves
mitochondrial respiratory function. SPD also inhibited kidney damage and fibrosis.
It is suggested that the effect of SPD on the improvement of cardiac function is
mediated by the promotion of autophagy and mitophagy in the heart and by the
reduction of the systemic chronic inflammatory response. This natural polyamine is
importantly involved in maintaining cellular homeostasis, and it affects several
processes including cell growth, proliferation and tissue regeneration; it also stimu-
lates the antineoplastic immune response and anti-aging properties, including tran-
scriptional and transductional modulation through several enzymes and nucleic
acid enzymes. Moreover, SPD promotes chaperone activity and ensures proteostasis
through anti-inflammatory and antioxidant properties, and it also enhances
mitochondrial function and cellular respiration [75].
Therefore, the effect of exogenous SDP administration was examined in aged rat
hearts [76]. SPD was shown to improve mitochondrial biogenesis by increasing
nuclear expression of PGC-1α (peroxisome proliferator-activated receptor gamma
coactivator alpha), which is mediated by enhanced NAD+-dependent deacetylase
activity of SIRT1 (sirtuin-1). These results suggest that SIRT1 is an essential inter-
mediary in the mechanism by which SPD stimulates mitochondrial biogenesis and
function in cardiac cells. In addition, findings showed that the administration of
SPD in vivo increased the activity of the antioxidant enzymes, superoxide
dismutase (SOD) and catalase (CAT), and improved mitochondrial respiratory
activity in the myocardium [76]. To date, there are not enough clinical trials to
evaluate the effects of SPD in reducing cardiovascular diseases. These findings
could guide new therapeutic strategies to counteract cardiac aging and prevent age-
related cardiovascular disease and, as a result, lay the foundation for better heart
disease treatments related to mitochondrial dysfunction [76].
3.5.5 Carvedilol
Carvedilol (CVL) belongs to the so-called α, β blockers, used to treat high blood
pressure and congestive heart failure, which are generally used for the treatment of
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cardiovascular disorders. CVL blocks sympathetic neural activation through antag-
onism of the β1, β2 and α1 adrenoceptors and it has demonstrated greater cardio-
vascular benefits than traditional β blockers in both humans and animals. However,
some benefits beyond decreased blood pressure were observed clinically, suggesting
the potential anti-inflammatory activity of CVL [77]. In addition, CVL is a known
membrane “fluidizer” that alters membrane structure and protein-lipid interactions
[78]. The most widely characterized inflammasome sensor in the heart is activated
in response to noninfectious stimuli, such as cell debris during acute myocardial
infarction. The NOD-like receptor (NLR) family, pyrin domain–containing protein
3 (NLRP3) inflammasome is a component of the inflammatory process. Activation
of the NLRP3 inflammasome triggers further myocardial damage indirectly through
the release of IL-1β and directly through the promotion of inflammatory cell death
via pyroptosis [79]. Pyroptosis is a type of caspase-1–dependent cell death, which is
often associated with inflammasome activation and IL-1β production characterized
by a loss of cell membrane integrity that leads to fluid influx and cell swelling [77].
Experimental studies have shown that strategies inhibiting the activation of the
NLRP3 inflammasome in the early reperfusion period after acute myocardial infarc-
tion reduce the overall size of the infarct and preserve normal cardiac function [79].
There is also evidence supporting the therapeutic value of NLRP3 inflammasome-
targeted strategies in experimental models and data supporting the role of the NLRP3
inflammasome in AMI and its consequences on adverse cardiac remodeling,
cytokine-mediated systolic dysfunction and heart failure [79]. Mechanistic analysis
revealed that CVL prevented lysosomal and mitochondrial damage and reduced
apoptosis-associated speck-like protein containing a CARD (ASC) oligomerization.
Additionally, CVL caused autophagic induction through a SIRT1-dependent pathway,
which inhibited the NLRP3 inflammasome [77].
CVL activates survival signaling of p-AKT and pluripotential markers in
cardiomyocytes (CM) after I/R. Cardioprotective actions of CVL are associated with
higher levels of the miR-199a-3p and miR-214 cardioprotective miRNAs [79]. CVL
stimulates the processing of microRNA (MIR)-199a-3p and miR-214 in the heart
through β-arrestin-1–biased β-1 adrenergic receptor (β1 AR) for cardioprotective
signaling. Studies show that using cultured cardiomyocyte and primary
cardiomyocyte cell lines, carvedilol is regulated by an increase in miR-199a-3p and
miR-214 in ventricular and atrial cardiomyocytes undergoing reperfusion ischemia
(I/R) injury.
3.5.6 Trehalose
It is known that trehalose, a natural disaccharide, protects cells against various
stresses. Trehalose is a natural disaccharide formed from two glucose molecules
with an α-type glycosidic junction. It is widely distributed in nonmammalian spe-
cies, such as fungi, yeasts, bacteria, invertebrates, insects and plants. Trehalose acts
to provide energy sources and protect the integrity of cells exposed to various
environmental stresses. Furthermore, it has also been shown that trehalose protects
against apoptosis in an autophagy-dependent manner. This natural disaccharide
improves cardiac remodeling, fibrosis and apoptosis after myocardial infarction and
attenuated heart dysfunction [80]. The cardioprotective effect of trehalose was not
observed in the heterozygous elimination of Beclin 1 in mice, indicating that these
protective effects are mediated by autophagy [81]. In this connection, trehalose
induces autophagy by facilitating the recruitment of LC3B to the autophagosomal
membranes in an mTOR-independent manner. The basal level of autophagy plays a
unique housekeeping role in the regulation of cardiac geometry and impaired
autophagy function and may contribute to various end-organ complications in
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insulin resistance and diabetes, including cardiomyopathy and nephropathy [82].
Autophagy is usually regulated by both mTOR-dependent and -independent mech-
anisms. The mTOR pathway is considered the classic autophagy regulation route,
which negatively regulates autophagy involving two functional complexes:
mTORC1 and mTORC2, with a much more predominant role for mTORC1.
Research findings suggest that trehalose may rescue the contractile myocardial
defect induced by insulin resistance and apoptosis, through autophagy associated
with the dephosphorylation of p38 MAPK and FOXo1 without affecting the phos-
phorylation of Akt [82]. Moreover, it was observed that trehalose not only activated
autophagy but also increased the expression of p62. In addition, the expression of
antioxidant genes regulated by trehalose through enhanced nuclear translocation of
Nrf2 in a p62-dependent manner leads to the suppression of OS. Therefore, a new
antioxidant action target for trehalose was proposed [83].
3.5.7 Lysosomal inhibitors blocking autophagy
Several lysosomal inhibitors such as bafilomycin A1 (BafA1), protease inhibitors
and chloroquine (CQ) have been used interchangeably to block autophagy in vitro
for lysosomal degradation. Only CQ and its derivate hydroxychloroquine (HCQ)
are FDA-approved drugs currently considered the principal compounds used in
clinical trials aimed for treating tumors through autophagy inhibition by impairing
autophagosome fusion [84]. They focus on how CQ inhibits autophagy and directly
compare its effects to those of BafA1. CQ mainly inhibits autophagy by impairing
autophagosome fusion with lysosomes rather than by affecting the acidity and/or
degradative activity of this organelle. Furthermore, CQ induces an autophagy-
independent severe disorganization of the Golgi and endolysosomal systems, which
impair autophagosome fusion. These results of Mauthe et al. suggest not using these
compounds (CQ and HCQ) for in vivo experiments because of multiple cellular
alterations caused by these drugs [84].
3.5.8 Resveratrol
Human clinical studies differ markedly in terms of the administered doses of
resveratrol, as well as in the duration of treatment. Overall, the most pronounced
effects of resveratrol include reduced body weight in obese patients and a partial
decrease in systolic blood pressure, as well as fasting blood glucose levels and HbA1c
in patients with diabetes mellitus in some clinical trials. Studies show that resveratrol
attenuates high glucose-induced cardiomyocyte apoptosis through AMPK, a serine/
threonine kinase that detects the state of cellular energy and regulates energy
homeostasis [85]. Activation of AMPK is involved in the determination of multiple
cellular processes including cell growth, apoptosis [86] and autophagy [87]. It is
known that AMPK activation could inhibit mTOR, the best characterized protein
kinase that negatively regulates autophagy [88]. Diabetic cardiomyopathy has shown
inhibition of autophagy and increased apoptosis in cardiac cells. The study of Xu et al.
demonstrated that using resveratrol in H9c2 cardiac myoblast cells exposed to high
glucose combined with palmitate suppressed autophagic activity and increased apo-
ptotic cell death. The H9c2 cells showed restored autophagy and attenuated apoptosis
in cells with diabetic stimuli when treated with resveratrol [89, 90].
3.5.9 Metformin
Metformin is a first-line antidiabetic drug that also activates autophagy and it
has cardiovascular protective effects [91], although a recent study reported
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otherwise, since metformin did not achieve the cardioprotective effect in an I/R
model in nonaged pigs [92]. This was proven because the protective effect of
metformin was abolished by treatment with chloroquine. This treatment inhibits
the fusion of lysosomes with autophagosomes and a high lysosomal pH, avoids the
final digestion stage and inhibits lysosomal activity [93].
However, a recent study by Chen Li et al. showed protection with metformin on
both cellular and animal models of aging and I/R injury. During aging, failure of
organelles results in the accumulation of macromolecules and impaired proteostasis
that result in the death of cardiac tissue. Necroptosis is a programmed cell death
involving receptor-interacting protein kinases 1 and 3 (RIP1, RIP3) that form the
necrosome and mixed lineage kinase domain-like protein (MLKL), which are sub-
sequently phosphorylated [94]. Besides, metformin treatment was able to restore
autophagy and reduce the accumulation of p62 in the aged myocardium, as well as
decrease the cardiac junction of p62-RIP1-RIP3 complexes and the RIP3 and MLKL-
induced phosphorylation. Therefore, metformin can break the unfavorable chain
mechanism of aging-related autophagy decrease that induces necroptosis [94].
3.6 Development of new autophagy modulators
Diabetes is a metabolic disorder that contributes to the development of cardiac
fibrosis and cardiomyopathy. Aminoguanidine (AG) inhibits advanced glycation
end products (AGEs) and advanced oxidation protein products (AOPP) accumu-
lated as a result of excessive oxidative stress in diabetes. In a recent work, we
investigated whether AG supplementation mitigates oxidative-associated cardiac
fibrosis in rats with type 2 diabetes mellitus (T2DM). In vivo experiments were
performed in a model of T2DM, and in vitro we used primary rat myofibroblasts to
confirm the antioxidant and antifibrotic effects of AG to determine if blocking the
receptor for AGEs (RAGE) prevents the fibrogenic response in myofibroblasts.
Diabetic rats exhibited an increase in cardiac fibrosis resulting from a high-fat,
high-carbohydrate diet (HFCD) and streptozotocin (STZ) injections. In contrast,
AG treatment significantly reduced cardiac fibrosis, alfa-smooth muscle actin
(αSMA) and oxidative-associated NOX4 and NOS2 mRNA expression [95]. In vitro
challenge of myofibroblasts with AG under T2DM conditions reduced intra- and
extracellular collagen type I expression and platelet-derived growth factor (PDGF),
transforming growth factor beta (TGFβ1) and collagen type 1 a 1 (COL1A1)
mRNAs, albeit with a similar expression of tumor necrosis factor alpha (TNFα) and
interleukin-6 (IL-6) mRNAs. This was accompanied by reduced phosphorylation of
extracellular signal-regulated kinase 1/2 (ERK1/2) and SMAD2/3 but not of AKT1/2/
3 and signal transducer and activator of transcription (STAT) pathways. RAGE
blockade further attenuated collagen type I expression in AG-treated
myofibroblasts. Thus, AG reduces oxidative stress-associated cardiac fibrosis by
reducing pERK1/2, pSMAD2/3 and collagen type I expression via AGE/RAGE sig-
naling in T2DM [95]. However, clinical studies need to be performed in order to
evaluate if AG treatment is useful and well-tolerated in human cardiac disease and
leads to a significant reduction in cardiac fibrosis as well as it modulates the
expression of oxidative and fibrogenic response in myofibroblasts like in this dis-
ease model.
Although the autophagy modulators described above have great potential, there
are currently no interventions aimed at modulating autophagy for human use.
Despite this, there are already licensed medicines for use in humans, which activate
or inhibit autophagy, such as rapamycin, chloroquine and HCQ, among others, that
were not developed for this purpose [96]. The main clinical obstacle is that they
have low pharmacological specificity for their objective, which is the autophagic
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process [84]. However, they have allowed us to know the main pathways by which
the autophagy process is activated or inactivated. Several pharmacological and
nutritional interventions are available to inhibit autophagy in the initiation, nucle-
ation, elongation, fusion or degradation phase [97]. In addition, several agents
modulate autophagy through multiple molecular mechanisms that are not yet char-
acterized (Table 1).
4. Conclusions
Alteration of proteostasis in heart tissue leads to diabetic cardiomyopathy char-
acterized by myocardial remodeling and interstitial fibrosis. Cardiomyocyte
proteotoxicity frequently faces the chronic accumulation of misfolded or unfolded
proteins that can lead to proteotoxic formation or aggregation of soluble peptides
with reduced cardiac function and arrhythmias. However, under pathological con-
ditions, autophagic flux may be an important strategy to prevent the progression of
various cardiovascular diseases due to risk of dysfunctional endothelial cells.
Autophagy is insufficient in endothelial cells isolated from individuals with diabetes
Increase AMPK Decrease mTORC1
Caloric restriction
Physical exercise
H2S
Metformin
Simvastatin
A-769662
Caloric restriction
Physical exercise
Everolimus
Rapamycin
Temsirolimus
Torins
Increase ROS Increase nuclear RF-1
Activation of MAPK
Antimycobacterial antibiotics
Carbon monoxide
Melatonin
IFNγ
Increase MAPK Inositol 1,4,5-triphosphate
receptor
Carbamazepine
Lithium
BECN1 activating peptide
Chromosome maintenance region-1
(CRM-1)
Hydroxycitrate
Resveratrol
Spermidine
Unknown
Chloramphenicol
Retinoic acid
Unknown
Trehalose
Trichostatin A
Examples of autophagy activators. A-769662, a new activator of AMP-activated protein kinase (AMPK); BECN1,
Beclin 1; H2S, hydrogen sulfide; mTORC1, target of rapamycin complex 1.
Table 1.
Autophageal processes susceptible to therapeutic modulation.
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mellitus. Moreover, it has been demonstrated that intact autophagy is essential for
eNOS signaling in endothelial cells. Nitric oxide-mediated vasodilation was pro-
moted by the induction of autophagy.
Autophagy has been shown to be a mechanism of fibrosis recovery and scarring
secondary to cell apoptosis and active in the perimeter of cardiovascular fibrotic
tissue. Autophagy inhibition has a beneficial effect on type 2 diabetes–induced
cardiomyopathy. These findings suggest that autophagy is diversely altered in
different types of diabetes-induced cardiac pathologies. Therefore, targeting
autophagy regulation may be a potential therapeutic strategy for diabetic
cardiomyopathy.
Moreover, the animal model of T2DM induced by STZ plus HFCD whose
diabetic response evokes pro-oxidative and profibrotic attenuated reactions in the
presence of AG suggests that this molecule may be part of autophagy therapy for
diabetic cardiomyopathy. Thus, AG reduces oxidative stress-associated cardiac
fibrosis by decreasing pERK1/2, pSMAD2/3 and collagen type I expression via
AGE/RAGE signaling in T2DM.
The knowledge of the molecules involved in mechanisms of proteostasis and
autophagy in cardiac cells and the role they play in various signaling pathways will
serve as an opportunity for the future design of therapeutic targets for the treat-
ment of fibrosis, alterations of cardiac tissue remodeling and cardiomyopathy.
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